APLMW (Apollomics) EBITDA Margin %: 0.00% (As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics EBITDA Margin %?

Apollomics APLMW -7.91% 31 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Apollomics ranks worse than 55.24% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apollomics's EBITDA for the six months ended in Dec. 2025 was $1.74 Mil. Apollomics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Apollomics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Apollomics  (NAS:APLMW) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Apollomics EBITDA Margin % Related Terms

Apollomics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Apollomics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics EBITDA Margin % Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -124.89

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -145.38 0.00

APLMW vs TVRD, PLRZ, LSTA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Apollomics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Apollomics's EBITDA Margin % falls into.


APLMW
31GF Score
Apollomics Inc APLMW
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Apollomics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-10.616/8.5
=-124.89 %

Apollomics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=1.741/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Apollomics (APLMW) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #522 out of 945 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Apollomics' EBITDA Margin % too high?
Apollomics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Apollomics ranks #522 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' EBITDA Margin % compare to TVRD and PLRZ?
According to the Biotechnology industry distribution chart, Apollomics ranks #522 out of 945 companies for EBITDA Margin %. This places Apollomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apollomics and its competitors. Apollomics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apollomics (APLMW), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price